Literature DB >> 8811344

Immune strategies utilized by lentivirus infected chimpanzees to resist progression to AIDS.

J Heeney1, W Bogers, L Buijs, R Dubbes, P ten Haaft, W Koornstra, H Niphuis, P Nara, V Teeuwsen.   

Abstract

HIV-1 infected chimpanzees are relatively resistant to the development of AIDS despite their close genetic relatedness to humans and their susceptibility to HIV-1 infection. We have systematically studied possible reasons for their relative ability to maintain T helper (Th) cell numbers and immune competence in the presence of chronic HIV-1 infection. Factors which may alone or together cause the loss in T-cell dependent immunity include: (i) the loss of Th cell function; (ii) the loss of Th cells; and (iii) the loss of capacity for Th cell renewal. Differences in the in vivo and in vitro responses of T lymphocytes from chimpanzees and humans were compared for evidence of HIV-1 related T-cell dysfunction. In contrast to HIV infected individuals, HIV-1 infected chimpanzees maintained strong Th cell proliferative and cytokine responses after receiving tetanus toxoid boosts. In addition there was no abnormal Th1 to Th2 shift as is suggested to occur in AIDS patients. There was no evidence of Th cell dysfunction such as increased level of programmed cell death (PCD) or immune activation in HIV-1 infected chimpanzees in contrast to HIV-1 infected asymptomatic humans. Anergy could be induced with HIV-1 gp120 in human but not chimpanzee Th lymphocytes. We then asked if there was a direct loss of chimpanzee CD4+ cells due to HIV-1 infection in vitro. Infection of chimpanzee CD4+ lymphocyte cultures with HIV-1 in the absence of CD8+ cells resulted in marked cytopathic effect with complete lysis and loss of cells within 3 weeks. We concluded that most chronic HIV-1 infected chimpanzees were able to maintain relatively stable CD4+ lymphocyte numbers despite CD4+ lymphocyte destruction due to direct effects of the virus. Furthermore, there was no evidence of indirect Th cell loss, since neither increased levels of anergy nor apoptosis were observed. Lymph node biopsies from HIV-1 infected chimpanzees revealed that MHC class II rich regions of lymph nodes remained intact, in contrast to the involution of these regions in infected humans. This suggested that chimpanzees may maintain the capacity for Th cell renewal by preserving this MHC class II lymphoid environment. The data presented in this paper suggests that chimpanzees may preserve this critical MHC class II-Th cell environment by dramatically suppressing extra-cellular virus load and that this may be in part mediated by soluble lentivirus suppressing factors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8811344     DOI: 10.1016/0165-2478(96)02554-0

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  10 in total

1.  Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.

Authors:  T Beaumont; S Broersen; A van Nuenen; H G Huisman; A M de Roda Husman; J L Heeney; H Schuitemaker
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Rapid CD4(+) T-cell loss induced by human immunodeficiency virus type 1(NC) in uninfected and previously infected chimpanzees.

Authors:  F J Novembre; J de Rosayro; S Nidtha; S P O'Neil; T R Gibson; T Evans-Strickfaden; C E Hart; H M McClure
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Transmission of simian immunodeficiency virus SIVcpz and the evolution of infection in the presence and absence of concurrent human immunodeficiency virus type 1 infection in chimpanzees.

Authors:  Jonathan L Heeney; Erik Rutjens; Ernst J Verschoor; Henk Niphuis; Peter ten Haaft; Scott Rouse; Hazel McClure; Sunita Balla-Jhagjhoorsingh; Willy Bogers; Mary Salas; Kathy Cobb; Luc Kestens; David Davis; Guido van der Groen; Valerie Courgnaud; Martine Peeters; Krishna K Murthy
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Multiple restrictions of human immunodeficiency virus type 1 in feline cells.

Authors:  Carsten Münk; Jörg Zielonka; Hannelore Constabel; Björn-Philipp Kloke; Benjamin Rengstl; Marion Battenberg; Francesca Bonci; Mauro Pistello; Martin Löchelt; Klaus Cichutek
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

5.  The efficacy of T cell-mediated immune responses is reduced by the envelope protein of the chimeric HIV-1/SIV-KB9 virus in vivo.

Authors:  Liljana Stevceva; Victor Yoon; Angela Carville; Beatriz Pacheco; Michael Santosuosso; Birgit Korioth-Schmitz; Keith Mansfield; Mark C Poznansky
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

6.  Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques.

Authors:  A Kaur; R M Grant; R E Means; H McClure; M Feinberg; R P Johnson
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

7.  Peripheral blood cytotoxic gammadelta T lymphocytes from patients with human immunodeficiency virus type 1 infection and AIDS lyse uninfected CD4+ T cells, and their cytocidal potential correlates with viral load.

Authors:  Sardar T A K Sindhu; Rasheed Ahmad; Richard Morisset; Ali Ahmad; José Menezes
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

8.  Human and simian immunodeficiency virus-mediated upregulation of the apoptotic factor TRAIL occurs in antigen-presenting cells from AIDS-susceptible but not from AIDS-resistant species.

Authors:  Nayoung Kim; Alicja Dabrowska; Richard G Jenner; Anna Aldovini
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

9.  Cell-intrinsic mechanism involving Siglec-5 associated with divergent outcomes of HIV-1 infection in human and chimpanzee CD4 T cells.

Authors:  Paula C Soto; Maile Y Karris; Celsa A Spina; Douglas D Richman; Ajit Varki
Journal:  J Mol Med (Berl)       Date:  2012-09-04       Impact factor: 4.599

10.  Inhibition of p38 MAPK in combination with ART reduces SIV-induced immune activation and provides additional protection from immune system deterioration.

Authors:  Omkar Chaudhary; Vivek Narayan; Felipe Lelis; Brandon Linz; Meagan Watkins; Ronald Veazey; Anna Aldovini
Journal:  PLoS Pathog       Date:  2018-08-30       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.